The ongoing Ebola outbreak in the Democratic Republic of the Congo, confirmed just last week, has escalated to become the fourth largest on record. This outbreak is particularly concerning due to its occurrence in a conflict zone, complicating containment efforts as historical data indicates significant challenges in such environments. Currently, there is no vaccine approved for the Bundibugyo species of the Ebola virus that is currently spreading.
However, preliminary scientific evidence suggests that Merck’s licensed Ebola vaccine, Ervebo, which is primarily designed for the Zaire ebolavirus, may provide some level of protection against the Bundibugyo strain. This potential cross-protection raises critical questions for regulatory bodies and pharmaceutical companies about the feasibility of deploying existing vaccines in unapproved contexts, especially in light of the urgent need to control the outbreak.
Open the full market picture for your next decision →
